Caribou cuts 32% of staff, further purges pipeline to focus on oncology CAR-T prospects
Caribou Biosciences is winnowing down for the second time in less than a year, dropping a leukemia CAR-T asset and laying off 32% of staff to home in on two lead allogeneic cell therapy candidates.
Caribou Biosciences is winnowing down for the second time in less than a year, dropping a leukemia CAR-T asset and laying off 32% of staff to home in on two lead allogeneic cell therapy candidates.
